

META GROWTH CORP.

**Condensed Interim Consolidated Financial Statements
(Unaudited)**

**For the three and six months ended February 29, 2020 and February 28, 2019
(Expressed in Canadian Dollars)**

**Notice of No Auditor Review of Condensed Interim Consolidated Financial Statements
For the three and six-month period ended February 29, 2020 and February 28, 2019**

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management and have been approved by the Audit Committee and Board of Directors of the Company.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of condensed interim financial statements by an entity's auditor.

(signed) "Mark Goliger"

(signed) "Mike Cosic"

Chief Executive Officer

Chief Financial Officer

May 21, 2020

Toronto, Ontario

META GROWTH CORP.
Condensed Interim Consolidated Statements of Financial Position
February 29, 2020 and August 31, 2019
(Unaudited - Expressed in Canadian Dollars)

	Notes	February 29 2020	August 31 2019
Assets			
Current			
Cash and cash equivalents	Note 4	\$ 15,737,644	\$ 7,528,849
Restricted cash		-	501,965
Trade and other receivables	Note 5	779,374	762,019
Inventory	Note 6	3,852,602	6,349,322
Prepaid expenses	Note 7	3,166,117	3,201,252
		\$ 23,535,737	\$ 18,343,407
Non-current			
Property and equipment	Note 8	\$ 10,443,173	\$ 10,621,620
Assets in process	Note 9	2,369,361	3,567,649
Right of use assets	Note 10	11,686,999	-
Prepaid expenses	Note 7	-	911,209
Loan receivable	Note 11	1,157,565	-
Intangible Assets		21,160,173	21,160,173
Goodwill		6,904,394	6,904,394
Total Assets		\$ 77,257,402	\$ 61,508,452
Liabilities			
Current			
Trade and other payables		\$ 3,203,204	\$ 3,637,227
Debt financing		-	9,000,000
Due to shareholders		410,000	410,000
Lease inducements		-	95,519
Lease obligation	Note 10	2,433,111	-
		\$ 6,046,315	\$ 13,142,746
Non-current			
Lease inducements		\$ -	290,305
Term loans	Note 12	13,563,163	-
Convertible debenture	Note 13	17,678,613	16,880,647
Deferred tax liability		3,890,515	3,529,008
Lease obligation	Note 10	9,391,531	-
Total Liabilities		\$ 50,570,137	\$ 33,842,706
Shareholders' Equity			
Share capital		\$ 75,612,403	\$ 67,016,838
Warrants		4,380,048	3,066,865
Contributed surplus		5,187,585	4,841,684
Accumulated other comprehensive loss		(428,571)	(428,571)
Accumulated deficit		(57,694,596)	(46,735,892)
Equity attributable to Meta Growth Corp.		27,056,869	27,760,924
Non-controlling interest	Note 14	(369,604)	(95,178)
Total Equity		\$ 26,687,265	\$ 27,665,746
Total Liabilities and Equity		\$ 77,257,402	\$ 61,508,452

Nature of operations and going concern (Note 1)
Subsequent events (Note 24)

These financial statements were authorized for issue by the Board of Directors on May 21, 2020. They are signed on the Company's behalf by:

"Michael Saliken"

Director

"Christian Sinclair"

Director

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.

META GROWTH CORP.**Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)**

	Three months ended		Six months ended	
	February 29	February 28	February 29	February 28
	2020	2019	2020	2019
Revenues				
Recreational – Retail	\$ 13,474,115	\$ 15,881,986	\$ 29,073,544	\$ 19,174,333
Medical – Education	163,294	320,114	360,453	814,995
	13,637,409	16,202,100	29,433,997	19,989,328
Cost of Goods Sold				
Recreational – Retail	9,491,363	10,925,275	20,241,541	13,173,529
Medical – Education	23,227	47,009	57,574	138,332
	9,514,590	10,972,284	20,299,115	13,311,591
Gross Profit	\$ 4,122,819	\$ 5,229,816	\$ 9,134,882	\$ 6,667,737
Expenses				
Advertising and marketing	116,437	93,782	304,296	352,272
Depreciation of property and equipment (Note 8)	787,565	457,956	1,581,160	581,807
Depreciation of right of use assets (Note 10)	796,674	-	1,582,141	-
Amortization of intangible assets	-	419,133	-	838,266
Share based compensation (Note 16)	125,371	373,464	345,901	671,171
Finance and other costs (Note 18)	1,662,735	1,496,476	3,698,584	3,756,757
General and administrative expenses (Note 26)	5,913,267	8,399,644	12,494,423	14,364,254
	\$ 9,402,049	\$ 11,240,455	\$ 20,006,505	\$ 20,564,527
Loss from operations before tax expense/(recovery)	(5,279,230)	(6,010,639)	(10,871,623)	(13,886,790)
Deferred tax expense/(recovery)	263,971	(366,978)	361,507	(366,978)
Net loss and comprehensive loss for the period	\$ (5,543,021)	\$ (5,643,661)	\$ (11,233,130)	\$ (13,519,812)
Net loss and comprehensive loss attributable to:				
Shareholders of Meta Growth Corp.	(5,374,779)	(5,411,349)	(10,958,704)	(13,117,976)
Non-controlling interest (Note 14)	(168,242)	(232,312)	(274,426)	(401,836)
	\$ (5,543,021)	\$ (5,643,661)	\$ (11,233,130)	\$ (13,519,812)
Net loss per share (Note 19)				
Basic and diluted	(0.03)	(0.03)	(0.06)	(0.08)

Certain comparative figures have been reclassified to conform to methods of presentation adopted in the current year (Note 25).

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.

META GROWTH CORP.

Condensed Interim Consolidated Statements of Changes in Equity
Three and six months ended February 29, 2020 and February 28, 2019
(Unaudited - Expressed in Canadian Dollars)

	Share Capital		Warrants	Contributed Surplus	Accumulated	Deficit	Non-Controlling Interest	Total
	Number of Shares	Amount	Amount		Other Comprehensive Loss			
Balance, August 31, 2018	135,700,258	\$ 25,794,995	\$ 2,952,235	\$ 1,245,455	\$ (428,571)	\$ (18,428,990)	\$ 4,956,331	\$ 16,091,455
Options exercised	1,625,000	243,750	-	-	-	-	-	243,750
Warrants exercised	1,775	1,598	-	-	-	-	-	1,598
Private Placement	21,978,020	20,000,000	-	-	-	-	-	20,000,000
Acquisition – The Green Company Ltd.	23,582,000	17,152,642	-	-	-	-	-	17,152,642
Acquisition – NAC Northern Alberta LP	2,173,913	1,500,000	-	-	-	(1,548,226)	266,417	218,191
Acquisition – New Leaf Emporium Inc.	649,880	400,000	-	-	-	-	-	400,000
Warrants issued	-	-	316,689	-	-	-	-	316,689
Convertible debentures	-	-	-	3,555,448	-	-	-	3,555,488
Share based compensation	-	-	-	671,171	-	-	-	671,171
Share issuance costs	-	(524,226)	-	-	-	-	-	(524,226)
Non-controlling interest	-	-	-	-	-	-	(401,836)	(401,836)
Net loss and comprehensive loss for the period	-	-	-	-	-	(13,117,976)	-	(13,117,976)
Balance, February 28 2019	185,710,846	\$ 64,568,759	\$ 3,268,924	\$ 5,472,074	\$ (428,571)	\$ (33,095,192)	\$ 4,820,912	\$ 44,606,905
Balance, August 31 2019	189,093,041	\$ 67,016,838	\$ 3,066,865	\$ 4,841,684	\$ (428,571)	\$ (46,735,892)	\$ (95,178)	\$ 27,665,746
Acquisition – The Green Company Ltd.	(2,007,860)	-	-	-	-	-	-	-
Convertible debentures (Note 13)	4,140,005	846,000	-	-	-	-	-	846,000
Bought deal financing (Note 15)	45,454,600	8,772,738	1,227,274	-	-	-	-	10,000,012
Share based compensation	-	-	-	345,901	-	-	-	345,901
Share issuance costs	-	(1,023,172)	85,909	-	-	-	-	(937,263)
Non-controlling interest	-	-	-	-	-	-	(274,426)	(274,426)
Net loss and comprehensive loss for the period	-	-	-	-	-	(10,958,704)	-	(10,958,704)
Balance, February 29 2020	236,679,786	\$ 75,612,403	\$ 4,380,048	\$ 5,187,585	\$ (428,571)	\$ (57,694,596)	\$ (369,604)	\$ 26,687,265

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.

META GROWTH CORP.
Condensed Interim Consolidated Statements of Cash Flows
Six months ended February 29, 2020 and February 28, 2019
(Unaudited - Expressed in Canadian Dollars)

	2020	2019
Operating Activities		
Net loss	\$ 11,233,130	\$ (13,519,812)
Adjustments for items not effecting cash and cash equivalents		
Accretion expense	797,966	939,589
Depreciation of property and equipment	1,581,160	581,807
Amortization of intangible assets	-	838,266
Depreciation of right of use assets	1,582,141	-
Amortization of lease inducement	-	100,208
Interest expense paid by shares	846,000	-
Accretion of lease liability	891,637	-
Issuance of warrants	85,909	129,952
Share-based compensation	345,901	671,171
Term loan restructuring loss	547,553	-
Loss on lease termination	129,771	-
Term loan – non-cash interest adjustment	17,164	-
Deferred tax expense / (recovery)	361,507	(366,978)
	(4,046,421)	(10,625,977)
Changes in non-cash working capital related to operations		
Trade and other receivables	(15,041)	(832,346)
Inventory	2,496,720	(5,918,488)
Prepaid expenses	238,190	(3,208,713)
Trade and other payables	(558,975)	1,673,889
Cash flows used in operating activities	(1,885,526)	(18,911,635)
Investing Activities		
Investments	-	(29,349)
Loan receivable	(1,157,565)	-
Acquisition of GreenCo, cash returned from escrow	501,965	(4,958,771)
Acquisition of assets in process	(44,786)	-
Acquisition of property and equipment	(253,829)	(9,876,706)
Cash flows used in investing activities	(954,215)	(14,864,826)
Financing Activities		
Debt financing repayment	-	(25,000,000)
Issuance of debt financing	4,000,000	9,000,000
Issuance of share capital	10,000,012	20,000,000
Issuance of convertible debentures	-	21,150,000
Issuance costs – convertible debentures	-	(905,170)
Lease liability payments	(1,928,304)	-
Exercise of warrants	-	1,598
Exercise of options	-	243,750
Share issuance costs	(1,023,172)	(524,226)
Cash flows provided by financing activities	11,048,536	23,965,952
Net increase (decrease) in cash and cash equivalents	8,208,795	(9,810,509)
Cash and cash equivalents, beginning of period	7,528,849	23,496,232
Cash and cash equivalents, end of period	\$ 15,737,644	\$ 13,685,723

Additional information on consolidated statements of cash flows (Note 20).

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements.

META GROWTH CORP.

Notes to the Condensed Interim Consolidated Financial Statements

Three and six months ended February 29, 2020 and February 28, 2019

(Unaudited - Expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

At the Company's annual and special meeting of shareholders held on February 19, 2020 (the "Meeting"), a special resolution was passed to change the name of the Company from National Access Cannabis Corp. to Meta Growth Corp. Subsequent to the Meeting, all filings and approvals were obtained and the Company's name was officially changed to Meta Growth Corp. ("META" or the "Company"). The Company, formerly Brassneck Capital Corp., was incorporated under the name Brassneck Capital Corp. pursuant to the provisions of the Business Corporations Act (Alberta) on June 15, 2015. The head office of the Company is located at Suite 200, 56 Aberfoyle Crescent, Toronto, Ontario M8X 2W4. The registered office of the Company is located at 1900, 520 3rd Avenue SW, Calgary, Alberta, Canada T2P 0R3.

The Company's common shares are listed on the TSX Venture Exchange ("TSXV"), under the trading symbol "META".

The Company and its subsidiaries are in the business of operating retail locations to sell and distribute cannabis and cannabis related products, effective October 2018 with the Cannabis Act coming into force. The Company also operates in the medical cannabis market by providing cannabinoid education and introducing patients to medical cannabis treatments via its national network of physicians and health professionals.

Going Concern Assumption

These condensed interim consolidated financial statements for the period ended February 29, 2020 have been prepared on the going concern basis, which assumes that the Company will continue to operate and will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

The Company is in the development stage of expanding by opening and acquiring cannabis retail locations throughout Canada. While these financial statements have been prepared on a going concern basis, the Company continues to remain dependent on its ability to obtain sufficient funding to sustain operations and continue with its current expansion projects. While the Company has been successful in raising financing in the past, there can be no assurance that it will be able to do so in the future. The continuing operations of the Company are dependent upon its ability to raise adequate financing and to commence profitable operations in the future and repay its liabilities arising from normal business operations as they become due. The Company has incurred losses from operations since incorporation and as at February 29, 2020 has an accumulated deficit of \$57,694,596. These factors indicate a material uncertainty that may cast significant doubt about the Company being able to continue as a going concern.

The condensed interim consolidated financial statements for the period ended February 29, 2020 do not reflect adjustments that would be necessary if the going concern basis was not appropriate. Consequently, adjustments would then be necessary to the carrying value of assets and liabilities, the reported revenues and expenses and the balance sheet classifications used. Such adjustments, if required, could be material.

Additionally, the Company's business could be significantly adversely affected by the effects of the recent outbreak of novel coronavirus ("COVID-19"). Several significant measures have been implemented in Canada and the rest of the world in response to the increased impact from COVID-19. The Company cannot accurately predict the impact COVID-19 will have on third parties' ability to meet their obligations with the Company, including due to uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In particular, the continued spread of COVID-19 globally could materially and adversely impact the Company's business including without limitation, employee health, workplace productivity, and other factors that will depend on future developments beyond the Company's control. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread

META GROWTH CORP.

Notes to the Condensed Interim Consolidated Financial Statements

Three and six months ended February 29, 2020 and February 28, 2019

(Unaudited - Expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN (continued)

health crisis that could adversely affect the economies and financial markets of many countries resulting in an economic downturn that could negatively impact the Company's financial position, financial performance, cash flows, and its ability to raise capital. The effects of COVID-19 are changing rapidly and the consequences cannot be reasonably estimated at this time but could have material adverse effects on the Company's operations.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Statement of Compliance

The Company's condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standards 34, "*Interim Financial Reporting*" ("IAS 34"), using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

The condensed interim consolidated financial statements do not include all of the information and disclosures required for full annual financial statements, and should be read in conjunction with the annual audited consolidated financial statements of the Company for the year ended August 31, 2019, which have been prepared in accordance with IFRS. In the opinion of the Company's management, the accompanying unaudited condensed interim consolidated financial statements contain only normal recurring adjustments that are necessary for a fair presentation of its financial position, financial performance, changes in equity and cash flows for the interim period. The accounting policies applied by the Company in these condensed interim consolidated financial statements are the same as those applied in the Company's annual consolidated financial statements for the year ended August 31, 2019. The unaudited condensed consolidated balance sheet as at February 29, 2020 was derived from the audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.

These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors on May 21, 2020.

2.2 Basis of measurement

The consolidated financial statements, presented in Canadian Dollars, have been prepared on a historical cost basis, except for cash, stock options and warrants which are measured at fair value.

2.3 Basis of consolidation

The consolidated financial statements include the financial results of the Company and its subsidiaries. The consolidated financial statements include the operating results of acquired entities from the date control commences until the day control ceases. Non-controlling interest in the equity of the Company's subsidiaries are shown separately in equity in the consolidated statements of financial position. All intercompany balances and transactions are eliminated upon consolidation.

The functional currency of the parent and all subsidiaries is the Canadian dollar, which is the presentation currency of the consolidated financial statements.

The operating subsidiaries the Company has control over are as follows:

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)**

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Subsidiaries	Percentage Ownership
National Access Canada Corporation	100%
NAC Southern Alberta Ltd.	100%
META West Coast Ltd.	100%
NAC Ontario Ltd.	100%
The Green Company Limited	100%
National Access Cannabis Management Corp	100%
NAC Northern Alberta Limited Partnership	100%
National Access Cannabis Medical Inc.	51%
NAC Bio Inc.	57.1%
NAC Thompson North Limited Partnership	49%
NAC Long Plain Limited Partnership	49%
NAC OCN Limited Partnership	49%
NAC Arrowhead Limited Partnership	49%

3. ADOPTION OF NEW STANDARDS**(i) IFRS 16, Leases**

On September 1, 2019 the Company adopted IFRS 16 – Leases. The new standard has significant changes to the lessee accounting by removing the distinction between operating and finance leases and requires lessees to recognize a lease liability reflecting its obligation for future lease payments and a right of use asset representing its right to use the underlying asset.

The Company has applied IFRS 16 using the modified retrospective approach. Under this approach comparative information has not been restated and continues to be reported under IAS 17. The Company has elected to use the following practical expedients in transitioning to IFRS 16:

- The Company has applied a single discount rate to a portfolio of leases with reasonably similar characteristics.
- The Company has elected to not include the initial direct costs associated with the lease in calculating the opening right of use asset.
- The Company has elected not to account for leases for which the lease term ends within 12 months as short-term leases.
- The Company has elected to record the right of use asset at an amount equal to the lease liability adjusted for prepaid or accrued lease payments.

Under IFRS 16, the Company has applied the following treatment to all leases:

- Right of use assets and lease liabilities are presented in the condensed interim consolidated statement of financial position and are measured at the present value of future lease payments discounted at the Company's incremental borrowing rate at the date of adoption.
- Right of use assets are amortized on a straight-line basis over the lease term and accretion expense is recognized on the lease liabilities using the effective interest method. Amortization of right of use assets and accretion expense are recognized in the consolidated statement of net loss and comprehensive loss.
- Total amount of cash paid, including both the principal and interest are presented in financing activities in the consolidated statement of cash flows.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)**

3. ADOPTION OF NEW STANDARDS (continued)

The Company's weighted average incremental borrowing rate at the date of transition on September 1, 2019 was approximately 14.79%. At the date of transition, the Company recognized right of use assets of \$12,599,918 and lease liabilities of \$12,216,478. The Company capitalized prepaid lease deposits and lease inducements amounting to \$383,440 to right of use assets on September 1, 2019 in accordance with IFRS 16.

A reconciliation of lease commitments as at September 1, 2019, outlining the impact of the transition to IFRS 16 is outlined below.

Operating lease commitments at August 31, 2019	19,940,698
Variable lease payments not recognized	(1,235,949)
Present value adjustment at September 1, 2019	(6,488,271)
Lease liability recognized at September 1, 2019	<u>12,216,478</u>

4. CASH AND CASH EQUIVALENTS

The Company's cash and cash equivalents consist of the following:

	February 29 2020	August 31 2019
Operating Cash	14,912,644	6,678,849
Guaranteed Investment Certificates	825,000	850,000
	<u>15,737,644</u>	<u>7,528,849</u>

5. TRADE AND OTHER RECEIVABLES

The Company's trade and other receivables consist of the following:

	February 29 2020	August 31 2019
Trade receivables	263,518	211,263
Sales taxes recoverable	515,856	550,756
	<u>779,374</u>	<u>762,019</u>

6. INVENTORY

Inventory consists of cannabis inventory and merchandise and accessories at retail locations which have been granted licenses.

	February 29 2020	August 31 2019
Cannabis inventory	2,968,288	5,939,276
Merchandise and accessories	884,315	410,046
	<u>3,852,602</u>	<u>6,349,322</u>

During the six months ended February 29, 2020, \$20,242,359 of inventory was recognized as an expense (\$13,186,540 for the six months ended February 28, 2019). There has been no provision for inventory recognized during the period.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****7. PREPAID EXPENSES**

The Company's prepaid expenses consist of the following:

	February 29 2020	August 31 2019
Prepaid inventory	712,374	1,396,245
Prepaid lease deposits	276,172	1,032,579
Other deposits	2,177,621	1,683,637
	<u>3,166,117</u>	<u>4,112,461</u>
Presented as:		
Current prepaid expenses	3,166,117	3,201,252
Long-term lease deposits	-	911,209
	<u>3,166,117</u>	<u>4,112,461</u>

The significant decrease is due to the reclassification of prepaid lease deposits to the right of use assets in accordance with IFRS 16.

8. PROPERTY AND EQUIPMENT

	Furniture And Equipment	Electronic Equipment	Information panels	Signs	Leasehold Improvements	Total
<u>Cost:</u>						
At August 31, 2019	964,591	3,164,089	14,233	241,325	8,605,431	12,989,669
Additions	28,985	90,058	-	14,531	120,256	253,829
Transferred from assets in process	29,594	251,568	-	44,808	822,915	1,148,885
At February 29, 2020	<u>1,023,170</u>	<u>3,505,714</u>	<u>14,233</u>	<u>300,664</u>	<u>9,548,602</u>	<u>14,392,383</u>
<u>Accumulated Depreciation</u>						
At August 31, 2019	182,816	637,902	14,233	51,540	1,481,558	2,368,049
Depreciation	100,957	576,066	-	29,501	874,636	1,581,160
At February 29, 2020	<u>283,773</u>	<u>1,213,968</u>	<u>14,233</u>	<u>81,041</u>	<u>2,356,194</u>	<u>3,949,210</u>
<u>Net carrying amounts:</u>						
At August 31, 2019	781,775	2,526,187	-	189,785	7,123,873	10,621,620
At February 29, 2020	<u>739,396</u>	<u>2,291,746</u>	<u>-</u>	<u>219,623</u>	<u>7,192,408</u>	<u>10,443,173</u>

9. ASSETS IN PROCESS

	Furniture And Equipment	Electronic Equipment	Signs	Leasehold Improvement	Total
<u>Cost:</u>					
At August 31, 2019	97,568	748,868	95,776	2,625,437	3,567,649
Additions	-	3,750	-	41,036	44,786
Transferred to property and equipment	(29,594)	(251,568)	(44,808)	(822,915)	(1,148,885)
Transferred to prepaid assets	-	-	-	(94,190)	(94,190)
At February 29, 2020	<u>67,974</u>	<u>501,050</u>	<u>50,968</u>	<u>1,749,369</u>	<u>2,369,361</u>
<u>Carrying amounts:</u>					
At August 31, 2019	97,568	748,868	95,776	2,625,437	3,567,649
At February 29, 2020	<u>67,974</u>	<u>501,050</u>	<u>50,968</u>	<u>1,749,369</u>	<u>2,369,361</u>

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)**

10. RIGHT OF USE ASSETS AND LEASE OBLIGATIONS

The Company has entered into various lease agreements to operate cannabis retail locations.

The following is a summary of the Company's right of use assets for the six months ended February 29, 2020:

Right of use assets	
Balance at September 1, 2019	12,599,918
Net additions	1,123,336
Disposals	(454,115)
Depreciation expense	(1,582,141)
Balance at February 29, 2020	<u>11,686,999</u>

The following is a summary of the Company's lease obligations for the six months ended February 29, 2020:

Lease obligations	
Balance at September 1, 2019	12,216,478
Net additions	1,095,576
Disposals	(450,745)
Cash outflows	(1,928,304)
Accretion expense	891,637
Balance at February 29, 2020	<u>11,824,642</u>
Presented as:	
Current lease obligation	2,433,111
Long-term lease obligation	9,391,531
	<u>11,824,642</u>

For the six months ended February 29, 2020, variable lease payments amounted to \$883,524.

The following is a summary of the contractual undiscounted cash outflows for lease obligations as of February 29, 2020:

Less than one year	4,025,687
One to three years	7,689,609
Three to five years	4,695,167
Five years onwards	1,793,321
Total undiscounted lease obligations	<u>18,203,783</u>

11. LOAN RECEIVABLE

During the six-month period ended February 29, 2020 the Company advanced \$1,103,032 to one of the winners of the Ontario cannabis store lottery for a new Kitchener cannabis retail location to fund the build out and start-up operations of the retail location. Pursuant to the terms of the agreement, the loan has an interest rate of 3% per annum. As at February 29, 2020 the total interest owing amounts to \$4,283. The principal balance is due and payable on the fifth anniversary date of the loan.

META GROWTH CORP.

Notes to the Condensed Interim Consolidated Financial Statements

Three and six months ended February 29, 2020 and February 28, 2019

(Unaudited - Expressed in Canadian Dollars)

11. LOAN RECEIVABLE (continued)

On January 27, 2020, the Company advanced \$50,000 to Sicamous Trading Company. Pursuant to the terms of the agreement, the loan has an interest of 6% per annum. As at February 29, 2020 the total interest owing amounts to \$250. The principal balance is due and payable on January 31, 2021.

12. TERM LOANS

On December 14, 2018, the Company entered into a \$9,000,000 loan agreement with Opaskwayak Cree Nation ("OCN"). The loan had a six-month term and carried an interest rate of 8% per annum payable monthly in arrears. In connection with the advance of the loan, the Company issued 900,000 warrants to OCN. Each warrant is redeemable for one Common Share in the capital of the Company at a price of \$1.08 per Common Share for a period of three years from the date of the loan agreement. The warrants issued were valued at \$186,732 using the Black-Scholes option pricing model and the following assumptions: fair value of common shares of \$1.08; expected life of 3 years; \$Nil dividends, 74% volatility, and risk-free interest rate of 2.2%.

On May 30, 2019, the Company converted its \$9,000,000 term loan with OCN, having a maturity date of June 14th, 2019 into an open line of credit. The line of credit carried an interest rate of 10% per annum with a December 14, 2019 maturity date. On November 18, 2019, the Company entered into an Amended Loan Agreement with OCN to extend the maturity date of the loan until December 31, 2022, at an annual interest rate of 10% and an annual administration fee of \$225,000. As a result of the debt restructuring, the Company recognized a \$547,553 debt restructuring loss in the statement of net loss and comprehensive loss for the six months ended February 29, 2020. The carrying value of the loan balance as at February 29, 2020 amounts to \$9,563,163.

On December 18, 2019, the Company entered into a Loan Agreement with OCN in respect of an unsecured loan, pursuant to which OCN will lend up to \$11,000,000 to the Company. The Loan has a 5- year term and any funds drawn down carry an interest rate of 10% per annum and incur an annual administration fee of 2.5% on the weighted average balance of the Loan advanced to the applicable date, paid annually to OCN each December 31. As at February 29, 2020 the Company has drawn a total of \$4,000,000.

13. CONVERTIBLE DEBENTURE

On November 23, 2018, the Company completed a private placement offering of special warrants that entitle the holders to receive 8% senior secured convertible debentures of the Company upon exercise of the special warrants. 21,150 special warrants were issued at a price of \$1,000 per special warrant for aggregate gross proceeds to the Company of \$21,150,000. In consideration of the services provided by the agents under the offering, the Company paid the agents a cash commission and other costs and expenses totaling \$905,170. On January 7, 2019 the Company received a receipt from the Ontario Securities Commission for the final short form prospectus. In accordance with the terms of the special warrant indenture governing the special warrants, all unexercised special warrants are deemed to be exercised, without further action on the part of the holder, on January 10, 2019, being the third business day following the date of the Receipt.

The Convertible Debentures bear interest at a rate of 8.00% per annum, payable semi-annually in arrears on May 31 and November 30 of each year, commencing May 31, 2019. The Convertible Debentures will be convertible at any time at the option of the holders thereof into common shares of the Company at a conversion price of \$1.08 per Common Share, subject to customary adjustment. The Convertible Debentures will mature on November 30, 2021.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****13. CONVERTIBLE DEBENTURE (continued)**

The Company used the residual value method to allocate the principal amount of the convertible debentures between the liability and equity components. The Company valued the debt component of the convertible debentures by calculating the present value of the principal and interest payments, discounted at a rate of 18.5%, being management's best estimate of the rate that a non-convertible debenture with similar terms would earn. The Company has allocated the proceeds from issuance between the estimated fair value of equity and debt components using an effective interest rate for the debt component of 18.5%. Based on this calculation, the liability component is \$17,678,613 and the residual equity component is \$3,418,081. For the six months ended February 29, 2020, the accreted interest on the debenture was \$797,966 (February 28, 2019 - \$363,675) and interest expense amounted to \$846,000 (February 28, 2019 - \$455,900).

On November 11, 2019, the Company provided notice to the registered holders of the Convertible Debentures that, pursuant to the terms of the convertible debenture indenture governing the terms of the Convertible Debentures dated November 23, 2018, between the Company and TSX Trust Company, the Company had elected to satisfy the entirety of the current interest obligation by the delivery of common shares in the capital of the Company. In accordance with the Debentures, interest in the amount of \$846,000 was due and payable to Debenture holders on November 30, 2019. The Common Shares issued in satisfaction of the Current Interest Obligation were issued at a price per Common Share of \$0.204 which equals the volume weighted average price for the ten consecutive trading days ending on November 27, 2019. As such, 4,140,005 common shares were issued to satisfy the interest obligation.

14. NON-CONTROLLING INTERESTS

The net changes in the non-controlling interests is as follows:

	NAC Bio Inc.	National Access Cannabis Medical Inc.	NAC Arrowhead Limited Partnership	NAC Long Plain Limited Partnership	NAC OCN Limited Partnership	NAC Thompson North Limited Partnership	Total
August 31, 2019	18,763	5,248	(88,949)	(52,122)	(26,614)	48,496	(95,178)
Net Income / (Loss)	(44,005)	(177,644)	(78,692)	19,711	(7,658)	13,862	(274,426)
February 29, 2020	(25,242)	(172,396)	(167,641)	(32,411)	(34,272)	62,358	(369,604)

15. BOUGHT DEAL FINANCING

On January 23, 2020, the Company entered into an agreement with Echelon Wealth Partners Inc. ("Echelon"), pursuant to which Echelon agreed to purchase, on a bought deal basis, 45,454,600 units of the Company at a price of \$0.22 per unit. On February 6, 2020, the Company closed the offering for total gross proceeds of \$10,000,012. Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at a price of \$0.29 for a period of 36 months from the closing date of the offering. The warrants were attributed a fair value of \$1,227,274 using the Black-Scholes option pricing model with the following assumptions: fair value of common shares of \$0.22; exercise price of options of \$0.29; expected life of three years; 30% volatility; and a risk-free interest rate of 1.30%.

The underwriters received a cash commission fee of 7% of gross proceeds as a result of conducting the bought deal financing. The Company issued warrants to the underwriters equal to 7% of the units sold in the offering, for a total of 3,181,822 warrants. The broker warrants entitle the holder to acquire one common share at an exercise price of \$0.29 on the date that is 36 months from the closing date. The warrants were attributed a fair value of \$85,909 using the Black-Scholes option pricing model with the

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****15. BOUGHT DEAL FINANCING (continued)**

following assumptions: fair value of common shares of \$0.22; exercise price of options of \$0.29; expected life of three years; 30% volatility; and a risk-free interest rate of 1.30%.

16. STOCK OPTION PLAN

The Company's stock option plan is applicable to directors, officers, employees and consultants of the Company. The options are granted at the Company's current fair market value of the Common Shares under terms and conditions determined by the board of directors of the Company. Under the terms of the plan, the options generally vest immediately or throughout a set time period and expire at various dates from the date of the grant. The board of directors has the right to modify vesting periods at the time of option grant. There were nil options issued for the six months ended February 29, 2020 compared to 2,310,000 for the six months ended February 28, 2019. The employee compensation expense related to options vested for the six months ended February 29, 2020 amounted to \$345,901, compared to the six months ended February 29, 2019 of \$671,171.

The number of options outstanding at February 29, 2020 amounts to 5,536,892 at a weighted average exercise price of \$0.66. The Company may issue up to 10% of the issued and outstanding Common Shares under its stock option plan.

17. SEGMENTED INFORMATION

Throughout the period ended February 29, 2020, the Company operated in three segments;

- i) Medical Cannabis Education - the Company owns and operates medical clinics to connect patients suffering from illnesses that may be helped by medical cannabis with Licensed Producers by providing such patients with the opportunity to access qualified health care practitioners and independent medical cannabis evaluations and advice.
- ii) Retail Cannabis Stores – The Company operates retail locations to sell and distribute cannabis and cannabis related products under its recreational retail cannabis brands META and NewLeaf.
- ii) Research - NAC Bio Inc. is a technology and research company established to advance clinical research regarding the medical benefits of cannabis for the treatment of chronic disease and illness.

All the Company's revenue earned and assets are located in Canada.

Operating segments

Three months ended February 29, 2020	Medical Cannabis Education	Retail Cannabis Stores	Research	Corporate	Total
Revenue	163,294	13,474,115	-	-	13,637,409
Cost of goods sold	23,227	9,491,363	-	-	9,514,590
Gross profit	140,067	3,982,752	-	-	4,122,819
Operating expenses	473,610	4,969,365	81,392	3,877,682	9,402,049
Loss from operations	(333,543)	(986,613)	(81,392)	(3,877,682)	(5,279,230)
Deferred tax expense	-	19,948	-	243,843	263,791
Net loss for the period	(333,543)	(1,006,561)	(81,392)	(4,121,525)	(5,543,021)

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****17. SEGMENTED INFORMATION (continued)**

Six months ended February 29, 2020	Medical Cannabis Education	Retail Cannabis Stores	Research	Corporate	Total
Revenue	360,453	29,073,544	-	-	29,433,997
Cost of goods sold	57,574	20,241,541	-	-	20,299,115
Gross profit	302,879	8,832,003	-	-	9,134,882
Operating expenses	1,005,692	9,992,113	102,671	8,906,029	20,006,505
Loss from operations	(702,813)	(1,160,110)	(102,671)	(8,906,029)	(10,871,623)
Deferred tax expense	-	117,664	-	243,843	361,507
Net loss for the period	(702,813)	(1,277,774)	(102,671)	(9,149,872)	(11,233,130)

Three months ended February 28, 2019	Medical Cannabis Education	Retail Cannabis Stores	Research	Corporate	Total
Revenue	320,114	15,881,986	-	-	16,202,100
Cost of goods sold	47,009	10,925,275	-	-	10,972,284
Gross profit	273,105	4,956,711	-	-	5,229,816
Operating expenses	598,928	4,965,013	168,302	5,508,212	11,240,455
Loss from operations	(325,823)	(8,302)	(168,302)	(5,508,212)	(6,010,639)
Deferred tax recovery	-	-	-	(366,978)	(366,978)
Net loss for the period	(325,823)	(8,302)	(168,302)	(5,141,234)	(5,643,661)

Six months ended February 28, 2019	Medical Cannabis Education	Retail Cannabis Stores	Research	Corporate	Total
Revenue	814,995	19,174,333	-	-	19,989,328
Cost of goods sold	138,332	13,173,259	-	-	13,311,591
Gross profit	676,663	6,001,074	-	-	6,677,737
Operating expenses	1,197,253	7,324,560	304,460	11,738,254	20,564,527
Loss from operations	(520,590)	(1,323,486)	(304,460)	(11,738,254)	(13,886,790)
Deferred tax recovery	-	-	-	(366,978)	(366,978)
Net loss for the period	(520,590)	(1,323,486)	(304,460)	(11,371,276)	(13,519,812)

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****18. FINANCE AND OTHER COSTS**

	Three months ended		Six months ended	
	February 29 2020	February 28 2019	February 29 2020	February 28 2019
Accretion expense on convertible debentures	408,436	363,675	797,966	363,675
Accretion expense on business acquisition	-	497,938	-	497,938
Accretion expense on warrants	-	29,045	-	77,976
Accretion expense on lease liabilities	442,992	-	891,637	-
Interest on convertible debenture	423,000	455,900	846,000	455,900
Interest on debt	258,536	149,918	485,647	718,411
Loss on restructuring of term loan	-	-	547,553	-
Loss on lease termination	129,771	-	129,771	-
Commitment fee	-	-	-	1,642,857
Total Finance and other costs	1,662,735	1,496,476	3,698,584	3,756,757

19. LOSS PER SHARE

The calculation of basic and diluted loss per share for the relevant periods is based on the following information:

	Three months ended		Six months ended	
	February 29 2020	February 28 2019	February 29 2020	February 28 2019
Basic loss per share				
Total net loss attributable to shareholders of Meta Growth Corp.	(5,374,779)	(5,411,349)	(10,958,704)	(13,117,976)
Weighted average number of common shares outstanding	202,713,611	184,078,585	195,517,832	174,574,102
Total net loss per common share, basic	(0.03)	(0.03)	(0.06)	(0.08)
Diluted loss per share				
Total net loss attributable to shareholders of Meta Growth Corp.	(5,374,779)	(5,411,349)	(10,958,704)	(13,117,976)
Weighted average number of common shares outstanding	202,713,611	184,078,585	195,517,832	174,574,102
Effect of dilutive potential shares	-	-	-	-
Weighted average number of common shares outstanding assuming dilution	202,713,611	185,078,585	195,517,832	174,574,102
Total net loss per common share, diluted	(0.03)	(0.03)	(0.06)	(0.08)

The treasury stock method is used to calculate loss per share and under this method stock options and warrants that are anti-dilutive are excluded from the calculation of diluted loss per share. For the periods ended February 29, 2020 and February 28, 2019, all outstanding options and warrants were considered anti-dilutive because the Company recorded a loss over those periods. The outstanding stock options and warrants that could dilute basic net loss per share in future periods but were not included in determining diluted net loss per share for the periods ending February 29, 2020 and February 28, 2019 because they are antidilutive are as follows:

	February 29 2020	February 28 2019
Stock options	5,536,892	8,711,892
Warrants	54,536,422	12,614,162
	60,073,314	21,326,054

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)**

20. ADDITIONAL INFORMATION ON CONSOLIDATED STATEMENT OF CASH FLOWS

Certain investing and financing activities do not require the use of cash, and accordingly, have been excluded from the consolidated statements of cash flow. Interest paid on debt and non-cash transactions are outlined below.

	February 29 2020	February 28 2019
Cash paid for interest on debt	485,657	718,411
Shares issued for convertible debenture interest	846,000	-
Debt forgiveness on acquisition	-	218,191

21. RELATED PARTY TRANSACTIONS

Related parties include the Company's key management personnel, independent directors and shareholders. Transactions with related parties were conducted in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and approved by the related parties.

A director of the Company was engaged to provide consulting services to the Company. During the six months ended February 29, 2020, the Company's expenses included \$20,000 (February 28, 2019 - \$60,000) related to these services. Effective October 31, 2019, the consulting agreement was terminated.

A Director of the Company is Chief of the Opaskwayak Cree Nation ("OCN"). On November 18, 2019, the Company entered into an Amended Loan Agreement with OCN to extend the maturity date of the loan until December 31, 2022, at an annual interest rate of 10% and an annual administration fee of \$225,000. As a result of the debt restructuring, the Company recognized a \$547,553 debt restructuring loss in the statements of net loss for the six months ended February 29, 2020.

On December 18, 2019, the Company entered into a Loan Agreement with OCN in respect of an unsecured loan, pursuant to which OCN will lend up to \$11,000,000 to the Company. The Loan has a 5-year term and any funds drawn down carry an interest rate of 10% per annum and incur an annual administration fee of 2.5% on the weighted average balance of the Loan advanced to the applicable date, paid annually to OCN each December 31. As at February 29, 2020 the Company has drawn \$4,000,000.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****22. FINANCIAL INSTRUMENTS**

The table below summarizes the carrying values of the Company's financial assets and financial liabilities:

		As at February 29 2020	As at August 31 2019
Financial assets:			
FVTPL			
	Cash and cash equivalents	15,737,644	7,528,849
	Restricted cash	-	501,965
Amortized cost			
	Trade receivables	263,518	211,263
	Loan receivable	1,157,565	-
Total financial assets		17,158,727	8,242,077
Financial liabilities:			
Financial liabilities at amortized cost			
	Trade and other payables	3,203,204	3,637,227
	Debt financing	13,563,163	9,000,000
	Due to shareholders	410,000	410,000
	Convertible debenture	17,678,613	16,880,647
Total financial liabilities		34,854,980	29,927,874

Financial Risk Management Objectives and Policies

The Company manages its exposure to a number of different financial risks arising from its operations as well as its use of financial instruments including market risk, credit risk and liquidity risk through its risk management strategy. The objective of the strategy is to support the delivery of the Company's financial targets while protecting its future financial security and flexibility. Financial risks are primarily managed and monitored through operating and financing activities. The financial risks are evaluated regularly with due consideration to changes in the key economic indicators and up-to-date market information.

A summary of the Company's risk exposures as it relates to financial instruments are reflected below:

Market risk**a) Currency risk**

The Company does not operate outside of Canada and therefore there is no inherent Currency risk.

b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's financial debt have fixed rates of interest and therefore expose the Company to fair value risk as the fixed rates limit or eliminate the cash flow risk from financial liabilities.

c) Price risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company does not hold any marketable securities or investments and therefore is exposed to limited price risk.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****22. FINANCIAL INSTRUMENTS (continued)****Liquidity Risk**

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company manages liquidity risk by continuously monitoring forecasts and actual cash flows and taking the necessary actions to maintain enough liquidity for operations and for growth objectives.

As at February 29, 2020 the Company had \$15,737,644 in cash and cash equivalents (August 31, 2019 - \$7,528,849). The Company is obligated to pay financial liabilities with total carrying amounts and contractual cash flows amounting to \$3,613,204 in the next 12 months (August 31, 2019 - \$4,047,227). As at February 29, 2020, the Company's financial liabilities have contractual maturities as summarized below:

	Due within					February 29 2020
	6 months	6 – 12 months	1-2 years	2-3 years	3 – 4 years	Total
Trade and other payables	3,203,204	-	-	-	-	3,203,204
Term loan	-	-	-	-	13,000,000	13,000,000
Due to shareholders	410,000	-	-	-	-	410,000
Convertible debenture	-	-	21,250,000	-	-	21,250,000
Total	3,613,204	-	21,250,000	-	13,000,000	37,863,204

	Due within					August 31 2019
	6 months	6 – 12 months	1-2 years	2-3 years	3 – 4 years	Total
Trade and other payables	2,956,781	680,446	-	-	-	3,637,227
Debt financing	-	-	-	-	9,000,000	9,000,000
Due to shareholders	410,000	-	-	-	-	410,000
Convertible debenture	-	-	-	21,250,000	-	21,250,000
Total	3,366,781	680,446	-	21,250,000	9,000,000	34,297,227

Credit Risk

Credit risk arises from cash held with banks and trade receivables. The Company does not have a significant concentration of risk with any customer and its maximum risk exposure is equal to the carrying value of the financial assets. The objective of managing credit risk is to prevent loss on financial assets. The Company minimizes credit risk as cash is held by reputable financial institutions. The Company is not aware of any material collection issues as there are no material amounts past due and no significant history of bad debts. The Company applies the IFRS 9 simplified model of recognizing lifetime expected credit losses for all trade receivables as these items do not have a significant financing component. Trade receivables are written off when there is no reasonable expectation of recovery. There has been no allowance taken as a result of applying the expected credit loss model.

23. CAPITAL MANAGEMENT

The capital structure of the Company consists of equity attributable to common shareholders, comprised of issued capital, treasury shares, equity-settled employee benefits reserve, deficit, and accumulated other comprehensive loss. The Company's objectives when managing capital are to: (i) preserve capital, (ii) obtain the best available net return, and (iii) maintain liquidity. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the capital management strategy during the period ended February 29, 2020.

META GROWTH CORP.**Notes to the Condensed Interim Consolidated Financial Statements****Three and six months ended February 29, 2020 and February 28, 2019****(Unaudited - Expressed in Canadian Dollars)****24. SUBSEQUENT EVENTS**

On March 23, 2020 the Company granted an aggregate of 3,964,601 Restricted Share Units ("RSU") to officers, directors and key employees of the Company, with vesting on March 23, 2021. Each vested RSU entitles the holder to receive one common share of the Company.

On May 21, 2020 the Company granted 300,000 RSUs to a director of the Company, with vesting on May 21, 2021. Each vested RSU entitles the holder to receive one common share of the Company.

Subsequent to the quarter end, COVID-19 resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures include, but are not limited to, imposing physical distancing, temporarily closing non-essential businesses, introducing self-imposed quarantine periods, and implementing travel restrictions. The Company has reacted by introducing initiatives such as restricting the number of customers allowed in a store at one time, incorporating floor decals to highlight appropriate physical distancing separation, inserting plexi-glass partitions at the cash counters, equipping stores with hand sanitizer dispensers, and increasing surface cleaning protocols. Furthermore, office-based employees have adopted a work-from-home model. Although the Company's services have been deemed as essential in the provinces in which it operates, if the impact of COVID-19 continues for an extended period of time, it may materially adversely effect the Company's business operations and future financial results.

25. COMPARATIVE FIGURES

Certain comparative figures have been reclassified to conform to the methods of presentation adopted in the current year. There has been no impact on the Financial Statements.

26. GENERAL AND ADMINISTRATIVE EXPENSES

	Three months ended		Six months ended	
	February 29	February 28	February 29	February 28
	2020	2019	2020	2019
General and administrative expenses				
Business taxes and licenses	12,957	47,631	36,201	91,127
Computer and technology expenses	236,197	244,822	466,003	419,954
Insurance	113,537	82,739	203,510	136,846
Interest and service charges	150,228	151,029	334,638	192,758
Office and store supplies	171,201	439,296	319,146	701,732
Professional fees	545,867	740,149	1,593,041	2,144,851
Consulting fees	277,925	652,992	476,789	1,326,444
Rental	518,223	1,686,148	883,524	2,729,755
Repairs and maintenance	21,558	17,430	34,595	52,699
Salaries and benefits	3,572,194	3,981,721	7,567,837	5,947,710
Security	103,647	76,249	156,064	106,025
Travel and entertainment	76,381	104,344	176,611	273,648
Utilities	113,352	175,094	246,464	240,705
	5,913,267	8,399,644	12,494,423	14,364,254

The General and Administrative expenses identified in the chart above include the costs associated with all the Company's operating segments (i.e. Retail Cannabis Stores, Medical Cannabis Education, Research, and Corporate).